SOCIETY OF
NUCLEAR MEDICINE
and molecular imaging

July 2017 Compared to Proposed Rule July 2018 Rates
Medicare Hospital Outpatient Prospective Payment System HOPPS (APC) Medicine Procedures, Radiopharmaceuticals, and Drugs

CY 2017 Final Rule CY 2018 Proposed Rule
Updated 7-14-2017 version

| Status Indicator | Item/Code/Service | OPPS Payment Status |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| A | Services furnished to a hospital outpatient that are paid under a fee schedule or payment system other than OPPS,* for example: | Not paid under OPPS. Paid by MACs under a fee schedule or payment system other than OPPS. |  |  |  |  |  |  |
|  | - Separately Payable Clinical Diagnostic Laboratory Services (Not subject to deductible or coinsurance.) | Services are subject to deductible or coinsurance unless indicated otherwise. |  |  |  |  |  |  |
| D | Discontinued Codes | Not paid under OPPS or any other Medicare payment system. |  |  |  |  |  |  |
| E1 | Items and Services: | Not paid by Medicare when submitted on outpatient claims (any outpatient bill type). |  |  |  |  |  |  |
|  | - Not covered by any Medicare outpatient benefit category <br> - Statutorily excluded by Medicare |  |  |  |  |  |  |  |
|  | - Not reasonable and necessary |  |  |  |  |  |  |  |
| E2 | Items and Services: <br> - for which pricing information and claims data are not available | Not paid by Medicare when submitted on outpatient claims (any outpatient bill type). |  |  |  |  |  |  |
| G | Pass-Through Drug/ Biologicals | Paid under OPPS; separate APC payment |  |  |  |  |  |  |
| K | NonPass-Through Drugs and nonimplantable Biologicals, including Therapeutic Radiopharmaceuticals | Paid under OPPS; separate APC payment |  |  |  |  |  |  |
| N | Items and Services packaged into APC rate | Paid under OPPS; payment is packaged into payment for other services. Therefore, there is no separate APC payment. |  |  |  |  |  |  |
| Q1 | STV-Packaged Codes | Paid under OPPS; Addendum B displays APC assignments when services are separately payable. <br> (1) Packaged APC payment if billed on the same claim as a HCPCS code |  |  |  |  |  |  |
|  |  | assigned status indicator " S ," " T ," or " V ." |  |  |  |  |  |  |
|  |  | (2) Composite APC payment if billed with specific combinations of services based on OPPS composite-specific payment criteria. Payment is packaged into a single payment for specific combinations of services. |  |  |  |  |  |  |
|  |  | (3) In other circumstances, payment is made through a separate APC |  |  |  |  |  |  |
| S | Procedure or Service, Not Discounted When Multiple | Paid under OPPS; separate APC payment |  |  |  |  |  |  |
| T | Significant Procedure, Multiple Procedure Reduction Applies | Paid under OPPS; separate APC payment |  |  |  |  |  |  |
| U | Brachytherapy Sources | Paid under OPPS; separate APC payment |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
| CPT/ | Trade | July- <br> 2017 | $\begin{gathered} 2018- \\ \mathbf{P} \end{gathered}$ | July- <br> 2017 | $\begin{gathered} 2018- \\ \mathbf{P} \end{gathered}$ | July 2017 Rates | $\begin{gathered} \hline \text { Proposed } \\ \text { Rule CY July } \\ 2018 \\ \hline \end{gathered}$ | \% |
| HCPCS | Description $\quad$ Name | APC | APC | SI | SI | Payment Rate | Payment Rate | Change |
| 38792 | Injection procedure; radioactive tracer for identification of sentinel node | 5591 | 5591 | Q1 | Q1 | \$333.08 | \$337.26 | 1.3\% |
| 38900 | Intraoperative identification (eg, mapping) of sentinel lymph node(s) includes injection of non-radioactive dye, when performed (List separately in addition to code for primary procedure) (For injection of radioactive tracer for identification of sentinel node, use 38792) <br> (Use in conjunction with $19302,19307,38500,38510$, <br> 38520,38525,38530,38542,38740,38745) | N/A | N/A | N | $N$ | N/A | N/A | N/A |
| 49427 | Injection procedure (eg, contrast media) for evaluation of previously placed peritoneal-venous shunt (For radiological supervision and interpretation, see 75809, 78291) | N/A | N/A | N | N | Packaged into APC rate | Packaged into APC rate | Packaged into APC rate |
| 51701 | Insertion of non-indwelling bladder catheter (eg, straight catheterization for residual urine) | 5734 | 5734 | Q1 | Q1 | \$100.02 | \$94.27 | -5.7\% |
| 51702 | Insertion of temporary indwelling bladder catheter; simple (eg, Foley) | 5734 | 5734 | Q1 | Q1 | \$100.02 | \$99.98 | 0.0\% |
| 51703 | Insertion of temporary indwelling bladder catheter; complicated (eg, altered anatomy, fractured catheter/balloon) | 5721 | 5721 | S | S | \$127.10 | \$129.59 | 2.0\% |
| 76376 | 3D rendering with interpretation and reporting of computed of computed tomography, magnetic resonance imaging, ultrasound, or other tomographic modality; not requiring image postprocessing on an independent workstation (Use 76376 in conjunction with codes(s) for base imaging procedure(s)) | N/A | N/A | N | N | Packaged into APC rate | Packaged into APC rate | Packaged into APC rate |


| CPT/ | Trade | $\begin{aligned} & \text { July- } \\ & 2017 \end{aligned}$ | $\begin{gathered} \text { 2018- } \\ \mathbf{P} \end{gathered}$ | July- <br> 2017 | $\begin{gathered} 2018- \\ \text { P } \end{gathered}$ | July 2017 <br> Rates | Proposed Rule CY July 2018 | \% |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| HCPCS | Description $\quad$ Name | APC | APC | SI | SI | Payment Rate | Payment Rate | Change |
| 76377 | 3D rendering with interpretation and reporting of computed of computed tomography, magnetic resonance imaging, ultrasound, or other tomographic modality; requiring image postprocessing on an independent workstation (Use 76377 in conjunction with codes(s) for base imaging procedure(s)) <br> (Do not report 76377 <br> in conjunction with 70496, 70498, 70544-70549, 71275, 71555, 72159, 72191, 72198, 73206, $73225,73706,73725,74175,74185,75557-75564,75635,76376,78000-78999,0066 \mathrm{~T}, 0067 \mathrm{~T}$, 0144T-0151T, 0159T) | N/A | N/A | N | N | Packaged into APC rate | Packaged into APC rate | Packaged into APC rate |
| 77080 | Dual-energy X-ray absorptiometry, bone density study, 1 or more sites; axial skeleton (eg, hips, pelvis, spine) | 5522 | 5522 | S | S | \$112.73 | \$96.54 | -14.4\% |
| 77085 | Dual-energy X-ray absorptiometry (DXA), bone density study, 1 or more sites; axial skeleton (eg, hips, pelvis, spine), including vertebral fracture assessment | 5522 | 5522 | Q1 | Q1 | \$112.73 | \$96.54 | -14.4\% |
| 77086 | Vertebral fractureassessment via dual-energy X -rayabsorptiometry (DXA) | 5521 | 5521 | Q1 | Q1 | \$59.86 | \$59.17 | -1.2\% |
| 77370 | Special medical radiation physics consultation | 5611 | 5611 | S | S | \$117.59 | \$122.37 | 4.1\% |

NUCLEAR MEDICINE Modified in 2013 INTRODUCTORY SECTION - The services listed do not include the radiopharmaceutical or drug. To separately report supply of diagnostic and therapeutic radiopharmaceutiacls nd drugs, use the appropriate supply code(s), in addition to the procedure code.

| 78012 | Thyroid uptake, single or multiple quantitative measurement(s) (including stimulation, suppression, or discharge, when performed) | 5591 | 5591 | S | S | \$333.08 | \$337.26 | 1.3\% |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 78013 | Thyroid imaging (including vascular flow, when performed) | 5591 | 5591 | S | S | \$333.08 | \$337.26 | 1.3\% |
| 78014 | Thyroid imaging (including vascular flow, when performed); with single or multiple uptake(s) quantitative measurement(s) (including stimulation, suppression, or discharge, when performed) | 5591 | 5591 | S | S | \$333.08 | \$337.26 | 1.3\% |
| 78015 | Thyroid carcinoma metastases imaging; limited are (eg, neck and chest only) | 5591 | 5591 | S | S | \$333.08 | \$337.26 | 1.3\% |
| 78016 | Thyroid carcinoma metastases imaging; with additional studies (eg, urinary recovery) | 5591 | 5591 | S | S | \$333.08 | \$337.26 | 1.3\% |
| 78018 | Thyroid carcinoma metastases imaging; whole body | 5591 | 5592 | S | S | \$333.08 | \$439.56 | 32.0\% |
| 78020 + | Thyroid carcinoma metastases uptake (Use in conjunction with code 78018 only) | N/A | N/A | N | N | Packaged into APC rate | Packaged into APC rate | Packaged into APC rate |
| 78070 | Parathyroid planar imaging (including subtraction, when performed) | 5591 | 5591 | S | S | \$333.08 | \$337.26 | 1.3\% |
| 78071 | Parathyroid planar imaging (including subtraction, when performed); with tomographic (SPECT) | 5591 | 5591 | S | S | \$333.08 | \$337.26 | 1.3\% |
| 78072 | Parathyroid planar imaging (including subtraction, when performed); with tomographic (SPECT), and concurrently acquired computed tomography (CT) for anatomical localization | 5592 | 5592 | S | S | \$429.13 | \$439.56 | 2.4\% |
| 78075 | Adrenal imaging, cortex and/or medulla | 5593 | 5593 | S | S | \$1,138.94 | \$1,163.30 | 2.1\% |
| 78099 | Unlisted endocrine procedure, diagnostic nuclear medicine | 5591 | 5591 | S | S | \$333.08 | \$337.26 | 1.3\% |
| 78102 | Bone marrow imaging; limited area | 5591 | 5591 | S | S | \$333.08 | \$337.26 | 1.3\% |
| 78103 | Bone marrow imaging; multiple areas | 5591 | 5591 | S | S | \$333.08 | \$337.26 | 1.3\% |
| 78104 | Bone marrow imaging; whole body | 5591 | 5591 | S | S | \$333.08 | \$337.26 | 1.3\% |
| 78110 | Plasma volume, radiopharmaceutical volume-dilution technique (separate procedure); single sampling | 5591 | 5593 | S | S | \$333.08 | \$1,163.30 | 249.3\% |
| 78111 | Plasma volume, radiopharmaceutical volume-dilution technique (separate procedure); multiple sampling | 5591 | 5593 | S | S | \$333.08 | \$1,163.30 | 249.3\% |
| 78120 | Red cell volume determination (separate procedure); single sampling | 5591 | 5591 | S | S | \$333.08 | \$337.26 | 1.3\% |
| 78121 | Red cell volume determination (separate procedure); multiple sampling | 5591 | 5592 | S | S | \$333.08 | \$439.56 | 32.0\% |
| 78122 | Whole blood volume determination, including separate measurement of plasma volume and red cell volume (radiopharmaceutical volume-dilution technique) | 5592 | 5592 | S | S | \$429.13 | \$439.56 | 2.4\% |
| 78130 | Red cell survival study; | 5591 | 5591 | S | S | \$333.08 | \$337.26 | 1.3\% |
| 78135 | Red cell survival study; differential organ/tissue kinetics (eg, splenic and/or hepatic sequestration) | 5591 | 5591 | S | S | \$333.08 | \$337.26 | 1.3\% |
| 78140 | Labeled red cell sequestration, differential organ/tissue, (eg, splenic and/or hepatic) | 5591 | 5591 | S | S | \$333.08 | \$337.26 | 1.3\% |
| 78185 | Spleen imaging only, with or without vascular flow (If combined with liver study, use procedures 78215 and 78216) | 5591 | 5591 | S | S | \$333.08 | \$337.26 | 1.3\% |
| 78190 | Kinetics, study of platelet survival, with or without differential organ/tissue localization | 5593 | NA | S | D | \$1,138.94 | NA | NA |


| CPT/ | Trade | $\begin{aligned} & \text { July- } \\ & 2017 \end{aligned}$ | $\begin{gathered} 2018- \\ \mathbf{P} \end{gathered}$ | July- <br> 2017 | $\begin{gathered} 2018- \\ \text { P } \end{gathered}$ | July 2017 Rates | $\begin{gathered} \hline \text { Proposed } \\ \text { Rule CY July } \\ 2018 \\ \hline \end{gathered}$ | \% |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| HCPCS | Description | APC | APC | SI | SI | Payment Rate | Payment Rate | Change |
| 78191 | Platelet survival study | 5591 | 5591 | S | S | \$333.08 | \$337.26 | 1.3\% |
| 78195 | Lymphatics and lymph nodes imaging (For sentinel node identification without scintigraphy imaging, use 38792) | 5592 | 5592 | S | S | \$429.13 | \$439.56 | 2.4\% |
| 78199 | Unlisted hematopoietic, Reticuloendothelial and lymphatic procedure, diagnostic nuclear medicine | 5591 | 5591 | S | S | \$333.08 | \$337.26 | 1.3\% |
| 78201 | Liver imaging; static only | 5593 | 5593 | S | S | \$1,138.94 | \$1,163.30 | 2.1\% |
| 78202 | Liver imaging; with vascular flow | 5593 | 5593 | S | S | \$1,138.94 | \$1,163.30 | 2.1\% |
| 78205 | Liver imaging (SPECT); | 5593 | 5593 | S | S | \$1,138.94 | \$1,163.30 | 2.1\% |
| 78206 | Liver image (SPECT); with vascular flow | 5592 | 5592 | S | S | \$429.13 | \$439.56 | 2.4\% |
| 78215 | Liver and spleen imaging; static only | 5591 | 5591 | S | S | \$333.08 | \$337.26 | 1.3\% |
| 78216 | Liver and spleen imaging; with vascular flow | 5591 | 5591 | S | S | \$333.08 | \$337.26 | 1.3\% |
| 78226 | Hepatobiliary system imaging, including gallbladder when present | 5591 | 5591 | S | S | \$333.08 | \$337.26 | 1.3\% |
| 78227 | Hepatobiliary system imaging, including gallbladder when present; with pharmacologic intervention, including quantitative measurement(s) when performed | 5592 | 5592 | S | S | \$429.13 | \$439.56 | 2.4\% |
| 78230 | Salivary gland imaging; | 5591 | 5591 | S | S | \$333.08 | \$337.26 | 1.3\% |
| 78231 | Salivary gland imaging; with serial images | 5591 | 5591 | S | S | \$333.08 | \$337.26 | 1.3\% |
| 78232 | Salivary gland function study | 5591 | 5591 | S | S | \$333.08 | \$337.26 | 1.3\% |
| 78258 | Esophageal motility | 5591 | 5591 | S | S | \$333.08 | \$337.26 | 1.3\% |
| 78261 | Gastric mucosa imaging | 5591 | 5591 | S | S | \$333.08 | \$337.26 | 1.3\% |
| 78262 | Gastroesophageal reflux study | 5591 | 5591 | S | S | \$333.08 | \$337.26 | 1.3\% |
| 78264 | Gastric Emptying Imaging Study (eg, solid, liquid or both) | 5591 | 5591 | S | S | \$333.08 | \$337.26 | 1.3\% |
| 78265 | Gastric Emptying Imaging Study (eg, solid, liquid or both); with small bowel transit | 5591 | 5591 | S | S | \$333.08 | \$337.26 | 1.3\% |
| 78266 | Gastric Emptying Imaging Study (eg, solid, liquid or both); with small bowel and colon transit, multiple days | 5592 | 5592 | S | S | \$429.13 | \$439.56 | 2.4\% |
| 78267 | Urea breath test, C-14 (isotopic); acquisition for analysis | N/A | N/A | A | A | N/A | N/A | N/A |
| 78268 | Urea breath test, C-14 (isotopic); analysis | N/A | N/A | A | A | N/A | N/A | N/A |
| 78270 | Vit B-12 absorption study (eg, Schilling test); without intrinsic factor | 5591 | 5591 | S | S | \$333.08 | \$337.26 | 1.3\% |
| 78271 | Vit B-12 absorption study (eg, Schilling test); with intrinsic factor | 5591 | 5591 | S | S | \$333.08 | \$337.26 | 1.3\% |
| 78272 | Vit B-12 absorption study combined, with and without intrinsic factor | 5591 | 5591 | S | S | \$333.08 | \$337.26 | 1.3\% |
| 78278 | Acute gastrointestinal blood loss imaging | 5591 | 5591 | S | S | \$333.08 | \$337.26 | 1.3\% |
| 78282 | Gastrointestinal protein loss | 5591 | 5591 | S | S | \$333.08 | \$337.26 | 1.3\% |
| 78290 | Intestine imaging (eg, ectopic gastric mucosa, Meckel's localization, volvulus) | 5591 | 5591 | S | S | \$333.08 | \$337.26 | 1.3\% |
| 78291 | Peritoneal-venous shunt patency test (eg, for LeVeen, Denver shunt) | 5591 | 5591 | S | S | \$333.08 | \$337.26 | 1.3\% |
| 78299 | Unlisted gastrointestinal procedure, diagnostic nuclear medicine | 5591 | 5591 | S | S | \$333.08 | \$337.26 | 1.3\% |
| 78300 | Bone and/or joint imaging; limited area | 5591 | 5591 | S | S | \$333.08 | \$337.26 | 1.3\% |
| 78305 | Bone and/or joint imaging; multiple areas | 5591 | 5591 | S | S | \$333.08 | \$337.26 | 1.3\% |
| 78306 | Bone and/or joint imaging; whole body | 5591 | 5591 | S | S | \$333.08 | \$337.26 | 1.3\% |
| 78315 | Bone and/or joint imaging; 3 three phase study | 5591 | 5591 | S | S | \$333.08 | \$337.26 | 1.3\% |
| 78320 | Bone and/or joint imaging; tomographic (SPECT) | 5592 | 5592 | S | S | \$429.13 | \$439.56 | 2.4\% |
| 78350 | Bone density (bone mineral content) study , 1 or more sites; single photon absorptiometry | N/A | N/A | E | E1 | N/A | N/A | N/A |
| 78351 | Bone density (bone mineral content) study , 1 or more sites; dual photon absorptiometry one or more sites | N/A | N/A | E | E1 | N/A | N/A | N/A |
| 78399 | Unlisted musculoskeletal procedure, diagnostic nuclear medicine | 5591 | 5591 | S | S | \$333.08 | \$337.26 | 1.3\% |
| 78414 | Determination of central c-v hemodynamics (non-imagine) (eg, ejection fraction with probe technique) with or without pharmacologic intervention or exercise, single or multiple determinations | 5592 | 5592 | S | S | \$429.13 | \$439.56 | 2.4\% |
| 78428 | Cardiac shunt detection | 5591 | 5591 | S | S | \$333.08 | \$337.26 | 1.3\% |
| 78445 | Non-cardiac vascular flow imaging (ie, angiography, venography) | 5591 | 5591 | S | S | \$333.08 | \$337.26 | 1.3\% |


| CPT/ | Trade | $\begin{aligned} & \text { July- } \\ & 2017 \end{aligned}$ | $\begin{gathered} 2018- \\ \text { P } \end{gathered}$ | July2017 | $\begin{gathered} 2018- \\ \text { P } \end{gathered}$ | July 2017 Rates | Proposed Rule CY July 2018 | \% |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| HCPCS | Description Name | APC | APC | SI | SI | Payment Rate | Payment Rate | Change |
| 78451 | Myocardial perfusion imaging, tomographic (SPECT) (including attenuation correction, qualitative or quantitative wall motion, ejection fraction by first pass or gated technique, additional quantification, when performed); single study, at rest or stress (exercise or pharmacologic) | 5593 | 5593 | S | S | \$1,138.94 | \$1,163.30 | 2.1\% |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT) (including attenuation correction, qualitative or quantitative wall motion, ejection fraction by first pass or gated technique, additional quantification, when performed); multiple studies, at rest and/or stress (exercise or pharmacologic) and/or redistribution and/or rest reinjection | 5593 | 5593 | S | S | \$1,138.94 | \$1,163.30 | 2.1\% |
| 78453 | Myocardial perfusion imaging, planar (including qualitative or quantitative wall motion, ejection fraction by first pass or gated technique, additional quantification, when performed); single study, at rest or stress (exercise or pharmacologic) | 5593 | 5593 | S | S | \$1,138.94 | \$1,163.30 | 2.1\% |
| 78454 | Myocardial perfusion imaging, planar (including qualitative or quantitative wall motion, ejection fraction by first pass or gated technique, additional quantification, when performed); multiple studies, at rest and/or stress (exercise or pharmacologic) and/or redistribution and/or rest reinjection | 5593 | 5593 | S | S | \$1,138.94 | \$1,163.30 | 2.1\% |
| 78456 | Acute venous thrombus imaging, peptide | 5593 | 5593 | S | S | \$1,138.94 | \$1,163.30 | 2.1\% |
| 78457 | Venous thrombosis imaging, venogram; unilateral | 5593 | 5593 | S | S | \$1,138.94 | \$1,163.30 | 2.1\% |
| 78458 | Venous thrombosis imaging, venogram; bilateral | 5591 | 5591 | S | S | \$333.08 | \$337.26 | 1.3\% |
| 78459 | Myocardial imaging, positron emission tomography (PET), metabolic evaluation | 5593 | 5593 | S | S | \$1,138.94 | \$1,163.30 | 2.1\% |
| 78466 | Myocardial imaging, infarct avid, planar; qualitative or quantitative | 5591 | 5591 | S | S | \$333.08 | \$337.26 | 1.3\% |
| 78468 | Myocardial imaging, infarct avid, planar; with ejection fraction by first pass technique | 5592 | 5592 | S | S | \$429.13 | \$439.56 | 2.4\% |
| 78469 | Myocardial imaging, infarct avid, planar; tomographic SPECT with or without quantification | 5593 | 5593 | S | S | \$1,138.94 | \$1,163.30 | 2.1\% |
| 78472 | Cardiac blood pool imaging, gated equilibrium; planar, single study at rest or stress (exercise and/or pharmacologic), wall motion study plus ejection fraction, with or without additional quantitative processing (or assessment of cardiac function by first pass technique, use 78496) | 5591 | 5591 | S | S | \$333.08 | \$337.26 | 1.3\% |
| 78473 | Cardiac blood pool imaging, gated equilibrium; multiple studies, wall motion study plus ejection fraction, at rest and stress (exercise and/or pharmacologic), with or without additional quantification | 5591 | 5591 | S | S | \$333.08 | \$337.26 | 1.3\% |
| 78481 | Cardiac blood pool imaging (planar), first pass technique; single study, at rest or with stress (exercise and/or pharmacologic), wall motion study plus ejection fraction, with or without quantification | 5592 | 5592 | S | S | \$429.13 | \$439.56 | 2.4\% |
| 78483 | Cardiac blood pool imaging (planar), first pass technique; multiple studies, at rest and with stress (exercise and/or pharmacologic), wall motion study plus ejection fraction, with or without quantification | 5592 | 5592 | S | S | \$429.13 | \$439.56 | 2.4\% |
| 78491 | Myocardial imaging, positron emission tomography (PET), perfusion; single study at rest or stress | 5594 | 5594 | S | S | \$1,321.53 | \$1,329.70 | 0.6\% |
| 78492 | Myocardial imaging, positron emission tomography (PET), perfusion; multiple studies at rest and/or stress | 5594 | 5594 | S | S | \$1,321.53 | \$1,329.97 | 0.6\% |
| 78494 | Cardiac blood pool imaging, gated equilibrium, SPECT, at rest, wall motion study plus ejection fraction, with or without quantitative processing | 5591 | 5591 | S | S | \$333.08 | \$337.26 | 1.3\% |
| 78496 + | Cardiac blood pool imaging, gated equilibrium, single study, at rest, with right ventricular ejection fraction by first pass technique (Use 78496 in conjunction with 78472) | N/A | N/A | N | N | Packaged into APC rate | Packaged into APC rate | Packaged into APC rate |
| 78499 | Unlisted cardiovascular procedure, diagnostic nuclear medicine | 5591 | 5591 | S | S | \$333.08 | \$337.26 | 1.3\% |
| 0331T | Myocardial sympathetic innervation, imaging, planar qualitative assessment | 5593 | 5593 | S | S | \$1,138.94 | \$1,163.30 | 2.1\% |
| 0332T | Myocardial sympathetic innervation, imaging, planar qualitative and quantitative assessment; with tomographic SPECT | 5593 | 5593 | S | S | \$1,138.94 | \$1,163.30 | 2.1\% |
| 0482T | Absolute quantitation of myocardial blood flow, positron emission tomography (PET), rest and stress | $\begin{aligned} & \text { New } \\ & 2018 \end{aligned}$ |  | $\begin{aligned} & \hline \text { New } \\ & 2018 \end{aligned}$ |  | New 2018 |  | New 2018 |
| 78579 | Pulmonary ventilation imaging (eg, aerosol or gas) | 5591 | 5591 | S | S | \$333.08 | \$337.26 | 1.3\% |
| 78580 | Pulmonary perfusion imaging (eg, particulate) | 5591 | 5591 | S | S | \$333.08 | \$337.26 | 1.3\% |
| 78582 | Pulmonary ventilation imaging (eg, aerosol or gas) and perfusion imaging | 5592 | 5592 | S | S | \$429.13 | \$439.56 | 2.4\% |


| CPT/ | Trade | $\begin{aligned} & \text { July- } \\ & 2017 \end{aligned}$ | $\begin{gathered} 2018 \\ \text { P } \end{gathered}$ | $\begin{aligned} & \text { July- } \\ & 2017 \end{aligned}$ | $\begin{gathered} 2018- \\ \text { P } \end{gathered}$ | July 2017 Rates | $\begin{gathered} \text { Proposed } \\ \text { Rule CY July } \\ 2018 \end{gathered}$ | \% |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| HCPCS | Description Name | APC | APC | SI | SI | Payment Rate | Payment Rate | Change |
| 78597 | Quantitative differential pulmonary perfusion, including imaging when performed | 5591 | 5591 | S | S | \$333.08 | \$337.26 | 1.3\% |
| 78598 | Quantitative differential pulmonary perfusion and ventilation (eg aerosol or gas), including imaging when performed | 5592 | 5592 | S | S | \$429.13 | \$439.56 | 2.4\% |
| 78599 | Unlisted respiratory procedure, diagnostic nuclear medicine | 5591 | 5591 | S | S | \$333.08 | \$337.26 | 1.3\% |
| 78600 | Brain imaging, less than 4 static views; | 5591 | 5591 | S | S | \$333.08 | \$337.26 | 1.3\% |
| 78601 | Brain imaging, less than 4 static views; with vascular flow | 5591 | 5591 | S | S | \$333.08 | \$337.26 | 1.3\% |
| 78605 | Brain imaging, minimum 4 static views; | 5592 | 5592 | S | S | \$429.13 | \$439.56 | 2.4\% |
| 78606 | Brain imaging, minimum 4 static views; with vascular flow | 5592 | 5592 | S | S | \$429.13 | \$439.56 | 2.4\% |
| 78607 | Brain imaging, tomographic (SPECT) | 5593 | 5593 | S | S | \$1,138.94 | \$1,163.30 | 2.1\% |
| 78608 | Brain imaging, positron emission tomography (PET); metabolic evaluation | 5594 | 5594 | S | S | \$1,321.53 | \$1,329.70 | 0.6\% |
| 78609 | Brain imaging, positron emission tomography (PET); perfusion evaluation | N/A | N/A | E | E1 | N/A | N/A | N/A |
| 78610 | Brain imaging, vascular flow only | 5592 | 5592 | S | S | \$429.13 | \$439.56 | 2.4\% |
| 78630 | Cerebrospinal fluid flow, imaging (not including introduction of material); cisternography (For injection procedure, see 61000-61070, 62270-62319) | 5592 | 5592 | S | S | \$429.13 | \$439.56 | 2.4\% |
| 78635 | Cerebrospinal fluid flow, imaging (not including introduction of material); ventriculography (For injection procedure, see 61000-61070, 62270-62294) | 5592 | 5592 | S | S | \$429.13 | \$439.56 | 2.4\% |
| 78645 | Cerebrospinal fluid flow, imaging (not including introduction of material); shunt evaluation (For injection procedure, see 61000-61070, 62270-62294) | 5592 | 5592 | S | S | \$429.13 | \$439.56 | 2.4\% |
| 78647 | Cerebrospinal fluid flow, imaging (not including introduction of material); tomographic (SPECT) | 5593 | 5593 | S | S | \$1,138.94 | \$1,163.30 | 2.1\% |
| 78650 | Cerebrospinal fluid leakage detection and localization | 5593 | 5593 | S | S | \$1,138.94 | \$1,163.30 | 2.1\% |
| 78660 | Radiopharmaceutical dacryocystography | 5591 | 5591 | S | S | \$333.08 | \$337.26 | 1.3\% |
| 78699 | Unlisted nervous system procedure, diagnostic nuclear medicine | 5591 | 5591 | S | S | \$333.08 | \$337.26 | 1.3\% |
| 78700 | Kidney imaging morphology | 5591 | 5591 | S | S | \$333.08 | \$337.26 | 1.3\% |
| 78701 | Kidney imaging morphology with vascular flow | 5591 | 5591 | S | S | \$333.08 | \$337.26 | 1.3\% |
| 78707 | Kidney imaging morphology with vascular flow and function, single study without pharmacological intervention | 5592 | 5592 | S | S | \$429.13 | \$439.56 | 2.4\% |
| 78708 | Kidney imaging morphology with vascular flow and function, single study, with pharmacological intervention (eg, angiotensin converting enzyme inhibitor and/or diuretic) | 5592 | 5592 | S | S | \$429.13 | \$439.56 | 2.4\% |
| 78709 | Kidney imaging morphology with vascular flow and function, multiple studies, with and without pharmacological intervention (eg, angiotensin converting enzyme inhibitor and/or diuretic) | 5592 | 5592 | S | S | \$429.13 | \$439.56 | 2.4\% |
| 78710 | Kidney imaging morphology tomographic (SPECT) | 5592 | 5592 | S | S | \$429.13 | \$439.56 | 2.4\% |
| 78725 | Kidney function study, non-imaging radioisotopic study | 5591 | 5591 | S | S | \$333.08 | \$337.26 | 1.3\% |
| 78730 + | Urinary bladder residual study (List separately in addition to code for primary procedure) (Use 78730 in conjunction with 78740) (For measurement of postvoid residual urine and/or bladder capacity by ultrasound, nonimaging, use 51798) (For ultrasound imaging of the bladder only, with measurement of postvoid residual urine when performed, use 76857) | N/A | N/A | N | N | Packaged into APC rate | Packaged into APC rate | Packaged into APC rate |
| 78740 | Ureteral reflux study (radiopharmaceutical voiding cystogram) For catheterization see 51701, 51702, 51703 | 5591 | 5591 | S | S | \$333.08 | \$337.26 | 1.3\% |
| 78761 | Testicular imaging with vascular flow | 5591 | 5591 | S | S | \$333.08 | \$337.26 | 1.3\% |
| 78799 | Unlisted genitourinary procedure; diagnostic nuclear medicine | 5591 | 5591 | S | S | \$333.08 | \$337.26 | 1.3\% |
| 78800 | Radiopharmaceutical localization of tumor or distribution of radiopharmaceutical agent(s); limited area | 5591 | 5591 | S | S | \$333.08 | \$337.26 | 1.3\% |
| 78801 | Radiopharmaceutical localization of tumor or distribution of radiopharmaceutical agent(s); multiple areas | 5591 | 5591 | S | S | \$333.08 | \$337.26 | 1.3\% |
| 78802 | Radiopharmaceutical localization of tumor or distribution of radiopharmaceutical agent(s); whole body, single day imaging | 5593 | 5593 | S | S | \$1,138.94 | \$1,163.30 | 2.1\% |


| CPT/ | Trade | $\begin{aligned} & \text { July- } \\ & 2017 \end{aligned}$ | $\begin{gathered} \text { 2018- } \\ \text { P } \end{gathered}$ | $\begin{aligned} & \text { July- } \\ & 2017 \end{aligned}$ | $\begin{gathered} 2018- \\ \text { P } \end{gathered}$ | July 2017 Rates | Proposed Rule CY July 2018 | \% |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| HCPCS | Description Name | APC | APC | SI | SI | Payment Rate | Payment Rate | Change |
| 78803 | Radiopharmaceutical localization of tumor or distribution of radiopharmaceutical agent(s); tomographic (SPECT) | 5592 | 5592 | S | S | \$429.13 | \$439.56 | 2.4\% |
| 78804 | Radiopharmaceutical localization of tumor or distribution of radiopharmaceutical agent(s); whole body, requiring 2 or more days imaging | 5593 | 5593 | S | S | \$1,138.94 | \$1,163.30 | 2.1\% |
| 78805 | Radiopharmaceutical localization of inflammatory process; limited area | 5593 | 5593 | S | S | \$1,138.94 | \$1,163.30 | 2.1\% |
| 78806 | Radiopharmaceutical localization of inflammatory process; whole body | 5593 | 5593 | S | S | \$1,138.94 | \$1,163.30 | 2.1\% |
| 78807 | Radiopharmaceutical localization of inflammatory process; tomographic (SPECT) (For imaging bone infectious or inflammatory disease with a bone imaging radiopharmaceutical, see 78300, 78305, 78306) | 5592 | 5592 | S | S | \$429.13 | \$439.56 | 2.4\% |
| 78808 | Injection procedure for radiopharmaceutical localization by non-imaging probe study, intravenous (eg, parathyroid adenoma) <br> (For sentinel lymph node identification, use 38792) | 5591 | 5591 | Q1 | Q1 | \$333.08 | \$337.26 | 1.3\% |
| 78811 | Positron emission tomography (PET) imaging; limited area (eg. chest, head/neck) | 5593 | 5593 | S | S | \$1,138.94 | \$1,163.30 | 2.1\% |
| 78812 | Positron emission tomography (PET) imaging; skull base to mid-thigh | 5594 | 5594 | S | S | \$1,321.53 | \$1,329.70 | 0.6\% |
| 78813 | Positron emission tomography (PET) imaging; whole body | 5594 | 5594 | S | S | \$1,321.53 | \$1,329.70 | 0.6\% |
| 78814 | Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; limited area (eg, chest, head/neck) | 5594 | 5594 | S | S | \$1,321.53 | \$1,329.70 | 0.6\% |
| 78815 | Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh | 5594 | 5594 | S | S | \$1,321.53 | \$1,329.70 | 0.6\% |
| 78816 | Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; whole body | 5594 | 5594 | S | S | \$1,321.53 | \$1,329.70 | 0.6\% |

(Report 78811-78816 only once per imaging session) (Computed tomography (CT) performed for other than attenuation correction and anatomical localization is reported using the appropriate site specific CT code with modifier 59)

| 78999 | Unlisted miscellaneous procedure, diagnostic nuclear medicine | 5591 | 5591 | S | S | \$333.08 | \$337.26 | 1.3\% |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| C9898 | Radiolabeled product provided during a hospital inpatient stay | N/A | N/A | N | N | N/A | N/A | N/A |
| 79005 | Radiopharmaceutical therapy, by oral administration (For monoclonal antibody by intravenous infusion, use 79403) | 5661 | 5661 | S | S | \$216.68 | \$230.41 | 6.3\% |
| 79101 | Radiopharmaceutical therapy, by intravenous administration (Do not report 79101 in conjunction with $36400,35410,79403,90780,96408$ ) (For monoclonal antibody by intravenous infusion, use 79403) (For infusion or instillation of nonantibody radioelement solution that includes three months follow-up care, use 77750) | 5661 | 5661 | S | S | \$216.68 | \$230.41 | 6.3\% |
| 79200 | Radiopharmaceutical therapy, by intracavitary administration | 5661 | 5661 | S | S | \$216.68 | \$230.41 | 6.3\% |
| 79300 | Radiopharmaceutical therapy, by interstitial radioactive colloid administration | 5661 | 5661 | S | S | \$216.68 | \$230.41 | 6.3\% |
| 79403 | Radiopharmaceutical therapy, radiolabeled monoclonal antibody by intravenous infusion (For pre-treatment imaging, see 78802, 78804) (Do not use in conjunction with 79101) | 5661 | 5661 | S | S | \$216.68 | \$230.41 | 6.3\% |
| 79440 | Radiopharmaceutical therapy, by intra-articular administration | 5661 | 5661 | S | S | \$216.68 | \$230.41 | 6.3\% |
| 79445 | Radiopharmaceutical therapy, by intra-arterial particulate administration (Do not report 79445 in conjunction with 90783, 96420) (Use appropriate procedural and radiological supervision and interpretation codes for the angiographic and interventional procedures provided pre-requisite to intra-arterial radiopharmaceutical therapy) | 5661 | 5661 | S | S | \$216.68 | \$230.41 | 6.3\% |
| 79999 | Radiopharmaceutical therapy, unlisted procedure | 5661 | 5661 | S | S | \$216.68 | \$230.41 | 6.3\% |
| 93017 | Cardiovascular stress test using maximal or submaximal treadmill or bicycle exercise, continuous electrocardiographic monitoring, and/or pharmacological stress; tracing only, without interpretation and report | 5722 | 5722 | Q1 | Q1 | \$232.31 | \$242.21 | 4.3\% |
| 96413 | Chemotherapy administration, intravenous infusion technique; up to one hour, single or initial substance/drug | 5694 | 5694 | S | S | \$279.45 | \$286.62 | 2.6\% |
| G0219 | PET imaging whole body; melanoma for non-covered indications | N/A | N/A | E | E1 | N/A | N/A | NA |
| G0235 | PET IMAGING, ANY SITE, NOT OTHERWISE SPECIFIED | N/A | N/A | E | E1 | N/A | N/A | NA |


| CPT/ |  | Trade | July2017 | $\begin{array}{\|c} 2018- \\ \mathbf{P} \end{array}$ | July- <br> 2017 | $\begin{gathered} 2018- \\ \mathrm{P} \end{gathered}$ | July 2017 Rates | Proposed Rule CY July 2018 | \% |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| HCPCS | Description | Name | APC | APC | SI | sı | Payment Rate | Payment Rate | Change |
| G0252 | PET imaging, full \& partial-ring PET scanner only, for initial diagnosis of breast cancer and/or surgical planning for breast cancer (eg, initial staging of axillary lymph nodes) |  | N/A | N/A | E | E1 | N/A | N/A | NA |
| RADIOPHARMACEUTICALS \& NUCLEAR MEDICINE RELATED DRUGS |  |  | APC | APC | SI | SI | July 2017 <br> Rates | Proposed Rule CY 2018 | \% Change |
| Q9969 | Non-HEU TC-99M Add-On per study dose Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | 95 percent NONHEU Product | 1442 | 1442 | K | K | \$10.00 | \$10.00 | \$0.00 |
| A4641 | Radiopharm dx agent noc RADIOPHARMACEUTICAL, DIAGNOSTIC, NOT OTHERWISE CLASSIFIED | NOC | N/A | N/A | N | N | Packaged into APC rate | Packaged into APC rate | Packaged into APC rate |
| A4642 | INDIUM IN-111 SATUMOMAB PENDETIDE, DIAGNOSTIC, PER STUDY DOSE, UP TO 6 MII I ICIIRIEC | ONCOSCINT® | N/A | N/A | N | N | Packaged into APC rate | Packaged into APC rate | Packaged into APC rate |
| A9500 | Tc99m sestamibi <br> TECHNETIUM TC-99M SESTAMIBI, DIAGNOSTIC, PER STUDY DOSE, UP TO 40 MILLICURIES | CARDIOLITE® / MIRALUMA® | N/A | N/A | N | N | Packaged into APC rate | Packaged into APC rate | Packaged into APC rate |
| A9501 | Technetium TC-99m teboroxime <br> TECHNETIUM TC-99M TEBOROXIME, DIAGNOSTIC, PER STUDY DOSE | $\begin{gathered} \text { CardioTec® } \\ \text { TEBO } \end{gathered}$ | N/A | N/A | N | N | Packaged into APC rate | Packaged into APC rate | Packaged into APC rate |
| A9502 | Tc99m tetrofosmin <br> TECHNETIUM TC-99M TETROFOSMIN, DIAGNOSTIC, PER STUDY DOSE | MYOVIEW® | N/A | N/A | N | N | Packaged into APC rate | Packaged into APC rate | Packaged into APC rate |
| A9503 | TECHNETIUM TC-99M MEDRONATE, DIAGNOSTIC, PER STUDY DOSE, UP TO 30 MILLICURIES | MDP | N/A | N/A | N | N | Packaged into APC rate | Packaged into APC rate | Packaged into APC rate |
| A9504 | Tc99m apcitide <br> TECHNETIUM TC-99M APCITIDE, DIAGNOSTIC, PER STUDY DOSE, UP TO 20 MILLICURIES | ACUTECT® | N/A | N/A | N | N | Packaged into APC rate | Packaged into APC rate | Packaged into APC rate |
| A9505 | TL201 thallium <br> THALLIUM TL-201 THALLOUS CHLORIDE, DIAGNOSTIC, PER MILLICURIE | THALLIUM 201 | N/A | N/A | N | N | Packaged into APC rate | Packaged into APC rate | Packaged into APC rate |
| A9507 | In111 capromab <br> INDIUM IN-111 CAPROMAB PENDETIDE, DIAGNOSTIC, PER STUDY DOSE, UP TO 10 MILLICURIES | PROSTASCINT® | N/A | N/A | N | N | Packaged into APC rate | Packaged into APC rate | Packaged into APC rate |
| A9508 | I131 iodobenguate, dx <br> IODINE I-131 IOBENGUANE SULFATE, DIAGNOSTIC, PER 0.5 MILLICURIE | I-131 MIBG | N/A | N/A | N | N | Packaged into APC rate | Packaged into APC rate | Packaged into APC rate |
| A9509 | lodine l-123 sod iodide mil <br> IODINE I-123 SODIUM IODIDE, DIAGNOSTIC, PER MILLICURIE | Use for 1-4 mCi doses of l-123 for whole body imaging for less than 1 mCi and thyroid imaging see A9516 | N/A | N/A | N | N | Packaged into APC rate | Packaged into APC rate | Packaged into APC rate |
| A9510 | TECHNETIUM TC-99M DISOFENIN, DIAGNOSTIC, PER STUDY DOSE, UP TO 15 MILLICURIES | DISIDA | N/A | N/A | N | N | Packaged into APC rate | Packaged into APC rate | Packaged into APC rate |
| A9512 | Tc99m pertechnetate TECHNETIUM TC99M PERTECHNETATE, DIAGNOSTIC, PER MILLICURIE | Straight Tech Technescan Technelite | N/A | N/A | N | N | Packaged into APC rate | Packaged into APC rate | Packaged into APC rate |
| A9515 | Choline C-11, diagnostic, per study dose, up to 20 millicuries | C-11 Choline Zevacor or Infacility production | NI | G | 9461 | G | \$5,700.00 | \$5,700.00 | 0.0\% |
| A9516 | lodine l-123 sod iodide mCi IODINE I-123 SODIUM IODIDE, DIAGNOSTIC, PER 100 MICROCURIES, UP TO 999 MICROCURIES |  | N/A | N/A | N | N | Packaged into APC rate | Packaged into APC rate | Packaged into APC rate |
| A9517 | I131 iodide cap, rx IODINE I-131 SODIUM IODIDE CAPSULE(S), THERAPEUTIC, PER MILLICURIE | Rx l-131 Capsules | 1064 | 1064 | K | K | \$40.69 | \$40.70 | 0.0\% |


| CPT/ |  | Trade | July- <br> 2017 | $\begin{gathered} 2018- \\ \text { P } \end{gathered}$ | July- <br> 2017 | $\begin{gathered} 2018- \\ P \end{gathered}$ | July 2017 Rates | Proposed Rule CY July 2018 | \% |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| HCPCS | Description | Name | APC | APC | SI | SI | Payment Rate | Payment Rate | Change |
| A9520 | Tc99 Tilmanocept Diag 0.5MCI <br> TECHNETIUM TC-99M TILMANOCEPT, DIAGNOSTIC, UP TO 0.5 MILLICURIES | Lymphoseek ${ }^{\text {TM }}$ | N/A | N/A | N | N | Packaged into APC rate | Packaged into APC rate | Packaged into APC rate |
| A9521 | Tc99m exametazime <br> TECHNETIUM TC-99M EXAMETAZIME, DIAGNOSTIC, <br> PER STUDY DOSE, UP TO 25 MILLICURIES | CERETEC® HMPAO | N/A | N/A | N | N | Packaged into APC rate | Packaged into APC rate | Packaged into APC rate |
| A9524 | I131 serum albumin, dx IODINE I-131 IODINATED SERUM ALBUMIN, DIAGNOSTIC, PER 5 MICROCURIES | I-131 Albumin | N/A | N/A | N | N | Packaged into APC rate | Packaged into APC rate | Packaged into APC rate |
| A9526 | Nitrogen N - 13 ammonia <br> NITROGEN N-13 AMMONIA, DIAGNOSTIC, PER STUDY DOSE, UP TO 40 MILLICURIES | N-13 | N/A | N/A | N | N | Packaged into APC rate | Packaged into APC rate | Packaged into APC rate |
| A9527 | Iodine I-125 sodium iodide IODINE I-125, SODIUM IODIDE SOLUTION, THERAPEUTIC, PER MILLICURIE |  | 2632 | 2632 | U | U | \$29.93 | \$26.08 | -12.9\% |
| A9528 | lodine l-131 iodide cap, dx IODINE I-131 SODIUM IODIDE CAPSULE(S), DIAGNOSTIC, PER MILLICURIE | $\underset{\substack{\text { I-131 } \\ \mathrm{mCi}}}{ }$ | N/A | N/A | N | N | Packaged into APC rate | Packaged into APC rate | Packaged into APC rate |
| A9529 | I131 iodide sol, dx IODINE I-131 SODIUM IODIDE SOLUTION, DIAGNOSTIC, PER MILLICURIE | $\underset{\substack{\text { Dx l-131 sol per } \\ \mathrm{mCi}}}{ }$ | N/A | N/A | N | N | Packaged into APC rate | Packaged into APC rate | Packaged into APC rate |
| A9530 | I131 iodide sol, rx IODINE I-131 SODIUM IODIDE SOLUTION, THERAPEUTIC, PER MILLICURIE | $\underset{\mathrm{mCi}}{\mathrm{Rx} \mathrm{I}-131 \text { sol per }}$ | 1150 | 1150 | K | K | \$12.56 | \$12.56 | 0.0\% |
| A9531 | 1131 max 100 uCi IODINE I-131 SODIUM IODIDE, DIAGNOSTIC, PER MICROCURIE (UP TO 100 MICROCURIES) | Dx l-131 up to uCi | N/A | N/A | N | N | Packaged into APC rate | Packaged into APC rate | Packaged into APC rate |
| A9532 | 1125 serum albumin, dx IODINE I-125 SERUM ALBUMIN, DIAGNOSTIC, PER 5 MICROCURIES |  | N/A | N/A | N | N | Packaged into APC rate | Packaged into APC rate | Packaged into APC rate |
| A9536 | Tc99m depreotide <br> TECHNETIUM TC-99M DEPREOTIDE, DIAGNOSTIC, PER STUDY DOSE, UP TO 35 MILLICURIES | NEOTEC® | N/A | N/A | N | N | Packaged into APC rate | Packaged into APC rate | Packaged into APC rate |
| A9537 | Tc99m mebrofenin <br> TECHNETIUM TC-99M MEBROFENIN, DIAGNOSTIC, PER STUDY DOSE, UP TO 15 MILLICURIES | CHOLETEC® | N/A | N/A | N | N | Packaged into APC rate | Packaged into APC rate | Packaged into APC rate |
| A9538 | TECHNETIUM TC-99M PYROPHOSPHATE, DIAGNOSTIC, PER STUDY DOSE, UP TO 25 MILLICURIES | PYROLTE® "Use this code for myocardial infarct imaging. Do not use this code for GBP, RVG or MUGA nocedures see | N/A | N/A | N | $N$ | Packaged into APC rate | Packaged into APC rate | Packaged into APC rate |
| A9539 | Tc99m pentetate <br> TECHNETIUM TC-99M PENTETATE, DIAGNOSTIC, PER STUDY DOSE, UP TO 25 MILLICURIES | Tc-99m DTPA | N/A | N/A | N | N | Packaged into APC rate | Packaged into APC rate | Packaged into APC rate |
| A9540 | TECHNETIUM TC-99M MACROAGGREGATED ALBUMIN, DIAGNOSTIC, PER STUDY DOSE, UP TO 10 | MAA | N/A | N/A | N | $N$ | Packaged into APC rate | Packaged into APC rate | Packaged into APC rate |
| A9541 | TECHNETIUM TC-99M SULFUR COLLOID, DIAGNOSTIC, PER STUDY DOSE, UP TO 20 MUl HCHDIE | SULFUR COLLOID® (SC) | N/A | N/A | N | N | Packaged into APC rate | Packaged into APC rate | Packaged into APC rate |
| A9542 | $\ln 111$ ibritumomab, dx <br> INDIUM IN-111 IBRITUMOMAB TIUXETAN, DIAGNOSTIC, PER STUDY DOSE, UP TO 5 MILLICURIES | Dx In-111 <br> ZEVALIN® | N/A | N/A | N | N | Packaged into APC rate | Packaged into APC rate | Packaged into APC rate |
| A9543 | Y90 ibritumomab, rx <br> YTTRIUM Y-90 IBRITUMOMAB TIUXETAN, THERAPEUTIC, PER TREATMENT DOSE, UP TO 40 MILLICURIES | Rx Y-90 ZEVALIN® | 1643 | 1643 | K | K | \$46,917.25 | \$47,111.90 | 0.4\% |


| CPT/ |  | Trade | July- <br> 2017 | $\begin{gathered} 2018- \\ \mathbf{P} \end{gathered}$ | July- <br> 2017 | $\begin{gathered} 2018 \\ P \end{gathered}$ | July 2017 <br> Rates | Proposed Rule CY July 2018 | \% |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| HCPCS | Description | Name | APC | APC | SI | SI | Payment Rate | Payment Rate | Change |
| A9544 | I131 tositumomab, dx IODINE I-131 TOSITUMOMAB, DIAGNOSTIC, PER STUDY DOSE | Dx BEXXAR® | N/A | N/A | N | D | Packaged into APC rate | Packaged into APC rate | Packaged into APC rate |
| A9545 | I131 tositumomab, rx <br> IODINE I-131 TOSITUMOMAB, THERAPEUTIC, PER TREATMENT DOSE | Rx BEXXAR® | N/A | N/A | E | D | Packaged into APC rate | Packaged into APC rate | Packaged into APC rate |
| A9546 | Co57/58 <br> COBALT CO-57/58, CYANOCOBALAMIN, DIAGNOSTIC, PER STUDY DOSE, UP TO 1 MICROCURIE | NYCOMED | N/A | N/A | N | N | Packaged into APC rate | Packaged into APC rate | Packaged into APC rate |
| A9547 | In111 oxyquinoline <br> INDIUM IN-111 OXYQUINOLINE, DIAGNOSTIC, PER 0.5 MILLICURIE | See new codes A9570 and A9571 for WBC and Platelet Imaging | N/A | N/A | N | N | Packaged into APC rate | Packaged into APC rate | Packaged into APC rate |
| A9548 | In111 pentetate <br> INDIUM IN-111 PENTETATE, DIAGNOSTIC, PER 0.5 <br> MILLICURIE | Indium DTPA | N/A | N/A | N | N | Packaged into APC rate | Packaged into APC rate | Packaged into APC rate |
| A9550 | Tc99m gluceptate <br> TECHNETIUM TC-99M SODIUM GLUCEPTATE, DIAGNOSTIC, PER STUDY DOSE, UP TO 25 MILLICURIES | GLUCOSCAN® | N/A | N/A | N | $N$ | Packaged into APC rate | Packaged into APC rate | Packaged into APC rate |
| A9551 | Tc99m succimer <br> TECHNETIUM TC-99M SUCCIMER, DIAGNOSTIC, PER STUDY DOSE, UP TO 10 MILLICURIES | DMSA | N/A | N/A | N | N | Packaged into APC rate | Packaged into APC rate | Packaged into APC rate |
| A9552 | F18 fdg <br> FLUORODEOXYGLUCOSE F-18 FDG, DIAGNOSTIC, PER STUDY DOSE, UP TO 45 MILLICURIES | FDG / F-18 | N/A | N/A | N | N | Packaged into APC rate | Packaged into APC rate | Packaged into APC rate |
| A9553 | Cr51 chromate <br> CHROMIUM CR-51 SODIUM CHROMATE, DIAGNOSTIC, PER STUDY DOSE, UP TO 250 MICROCURIES |  | N/A | N/A | N | N | Packaged into APC rate | Packaged into APC rate | Packaged into APC rate |
| A9554 | 1125 iothalamate, dx IODINE I-125 SODIUM IOTHALAMATE, DIAGNOSTIC, PER STUDY DOSE, UP TO 10 MICROCURIES |  | N/A | N/A | N | N | Packaged into APC rate | Packaged into APC rate | Packaged into APC rate |
| A9555 | Rb82 rubidium <br> RUBIDIUM RB-82, DIAGNOSTIC, PER STUDY DOSE, UP TO 60 MILLICURIES | $\begin{gathered} \text { Rb-82 } \\ \text { CardioGen82 } \end{gathered}$ | N/A | N/A | N | N | Packaged into APC rate | Packaged into APC rate | Packaged into APC rate |
| A9556 | Ga67 gallium <br> GALLIUM GA-67 CITRATE, DIAGNOSTIC, PER MILLICURIE | GALLIUM | N/A | N/A | N | N | Packaged into APC rate | Packaged into APC rate | Packaged into APC rate |
| A9557 | Tc99m bicisate <br> TECHNETIUM TC-99M BICISATE, DIAGNOSTIC, PER STUDY DOSE, UP TO 25 MILLICURIES | NEUROLITE® | N/A | N/A | N | N | Packaged into APC rate | Packaged into APC rate | Packaged into APC rate |
| A9558 | Xe133 xenon 10 mci <br> XENON XE-133 GAS, DIAGNOSTIC, PER 10 MILLICURIES | Xenon | N/A | N/A | N | N | Packaged into APC rate | Packaged into APC rate | Packaged into APC rate |
| A9559 | Co57 cyano COBALT CO-57 CYANOCOBALAMIN, ORAL, DIAGNOSTIC, PER STUDY DOSE, UP TO 1 MICROCURIE | Shillings Study Rubratope 57 Cobatope 57 | N/A | N/A | N | $N$ | Packaged into APC rate | Packaged into APC rate | Packaged into APC rate |
| A9560 | TECHNETIUM TC-99M LABELED RED BLOOD CELLS, DIAGNOSTIC, PER STUDY DOSE, UP TO 30 MILLICURIES | ULIRATAG® or CoId PYP 99 m Tc Code to be used for both the invivolinvitro methods of tagging Red Bland Cells | N/A | N/A | N | N | Packaged into APC rate | Packaged into APC rate | Packaged into APC rate |
| A9561 | TC99m oxidronate <br> TECHNETIUM TC-99M OXIDRONATE, DIAGNOSTIC, PER STUDY DOSE, UP TO 30 MILLICURIES | HDP® | N/A | N/A | N | N | Packaged into APC rate | Packaged into APC rate | Packaged into APC rate |
| A9562 | TC99m mertiatide <br> TECHNETIUM TC-99M MERTIATIDE, DIAGNOSTIC, PER STUDY DOSE, UP TO 15 MILLICURIES | MAG-3® | N/A | N/A | N | N | Packaged into APC rate | Packaged into APC rate | Packaged into APC rate |


| CPT/ |  | Trade | July- <br> 2017 | $\begin{gathered} 2018- \\ \mathbf{P} \end{gathered}$ | July- <br> 2017 | $\begin{gathered} 2018 \\ \text { P } \end{gathered}$ | July 2017 Rates | Proposed Rule CY July 2018 | \% |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| HCPCS | Description | Name | APC | APC | SI | SI | Payment Rate | Payment Rate | Change |
| A9563 | P32 Na phosphate <br> SODIUM PHOSPHATE P-32, THERAPEUTIC, PER MILLICURIE |  | 1675 | 1675 | K | K | \$56.64 | \$56.64 | 0.0\% |
| A9564 | P32 chromic phosphate CHROMIC PHOSPHATE P-32 SUSPENSION, THERAPEUTIC, PER MILLICURIE | Phosphocol P-32 | 1676 | NA | K | N | \$71.14 | Packaged into APC rate | Packaged into APC rate |
| A9566 | Tc99m fanolesomab <br> TECHNETIUM TC-99M FANOLESOMAB, DIAGNOSTIC, PER STUDY DOSE, UP TO 25 MILLICURIES | NeutroSpec ${ }^{\text {™ }}$ | N/A | N/A | N | N | Packaged into APC rate | Packaged into APC rate | Packaged into APC rate |
| A9567 | Technetium TC-99m aerosol <br> TECHNETIUM TC-99M PENTETATE, DIAGNOSTIC, AEROSOL, PER STUDY DOSE, UP TO 75 MILLICURIES | DTPA Aerosol For Lung Ventilation Studies | N/A | N/A | N | N | Packaged into APC rate | Packaged into APC rate | Packaged into APC rate |
| A9568 | Technetium tc99m arcitumomab <br> TECHNETIUM TC-99M ARCITUMOMAB, DIAGNOSTIC, PER STUDY DOSE, UP TO 45 MILLICURIES | CEA-SCAN® | N/A | N/A | N | N | Packaged into APC rate | Packaged into APC rate | Packaged into APC rate |
| A9569 | Technetium TC-99m auto WBC TECHNETIUM TC-99M EXAMETAZIME LABELED AUTOLOGOUS WHITE BLOOD CELLS, DIAGNOSTIC, PER STUDY DOSE | Use this code for <br> infection or <br> inflammation imaging <br> do not use this code for <br> brain imaging see | N/A | N/A | N | N | Packaged into APC rate | Packaged into APC rate | Packaged into APC rate |
| A9570 | Indium In-111 auto WBC <br> 'INDIUM IN-111 LABELED AUTOLOGOUS WHITE BLOOD CELLS, DIAGNOSTIC, PER STUDY DOSE | When prepared with patient WBC use this new code do not use A9547 | N/A | N/A | N | N | Packaged into APC rate | Packaged into APC rate | Packaged into APC rate |
| A9571 | Indium IN-111 auto platelet INDIUM IN-111 LABELED AUTOLOGOUS PLATELETS, DIAGNOSTIC, PER STUDY DOSE | When prepared with patient platelets use this new code do not use A9547 | N/A | N/A | N | N | Packaged into APC rate | Packaged into APC rate | Packaged into APC rate |
| A9572 | Indium In-111 pentetreotide 'INDIUM IN-111 PENTETREOTIDE, DIAGNOSTIC, PER STUDY DOSE, UP TO 6 MILLICURIES | Octreoscan® | N/A | N/A | N | N | Packaged into APC rate | Packaged into APC rate | Packaged into APC rate |
| A9580 | Sodium Fluoride F-18, <br> Sodium Fluoride F-18, diagnostic, per study dose, up to 30 millicuries | F-18, NaF, Sodium Fluoride | N/A | N/A | N | N | Packaged into APC rate | Packaged into APC rate | Packaged into APC rate |
| A9582 | Iobenguane, I-123, diagnostic, per study dose, up to 15 millicuries | I-123 MIBG AdreView NDC 17156-0235-01 | N/A | N/A | N | N | Packaged into APC rate | Packaged into APC rate | Packaged into APC rate |
| A9584 | lodine I-123 ioflupane, diagnostic, per study dose, (up to 5 millicuries) | $\begin{aligned} & \text { DaTscan@ NDC } \\ & \# 17156-210-01 \end{aligned}$ | N/A | N/A | N | N | Packaged into APC rate | Packaged into APC rate | Packaged into APC rate |
| A9586 | Florbetapir F18 <br> FLORBETAPIR F18, DIAGNOSTIC, PER STUDY DOSE, UP TO 10 MILLICURIES | Amyvid ${ }^{\text {TM }}$ NDC \#0002-1200-01 | 1664 | N | G | N | \$2,756.00 | Packaged into APC rate | Packaged into APC rate |
| A9587 | Gallium ga-68, dotatate, diagnostic, 0.1 millicurie | (NETSPOT ${ }^{\text {TM }}$ ), NDC (69488-00140) AAA ) FDAapproved (6/2/16) PET imaging agent for the localization of somatostatin receptor-positive neuroendocrine tumors | 9056 | 9056 | G | G | \$66.74 | \$66.74 | 0.0\% |


| CPT/ |  | Trade | July- <br> 2017 | $\begin{gathered} 2018- \\ P \end{gathered}$ | July- <br> 2017 | $\begin{gathered} 2018- \\ \mathbf{P} \end{gathered}$ | July 2017 Rates | Proposed Rule CY July 2018 | \% |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| HCPCS | Description | Name | APC | APC | sı | SI | Payment Rate | Payment Rate | Change |
| A9588 | Fluciclovine f-18, diagnostic, 1 millicurie | (Axumin ${ }^{\text {TM }}$ ), Blue Earth Diagnostic (BED) FDAapproved (5/31/16), a PET imaging agent for detecting biochemical recurrence of prostate cancer | 9052 | 9052 | G | G | \$389.55 | \$389.55 | 0.0\% |
| A9597 | Positron emission tomography radiopharmaceutical, diagnostic, for tumor identification, not otherwise classified | Generic code, use for newly FDA approved PET diagnostic radiopharmaceutic als | NA | NA | NI | N | Packaged into APC rate | Packaged into APC rate | Packaged into APC rate |
| A9598 | Positron emission tomography radiopharmaceutical, diagnostic, for non-tumor identification, not otherwise classified | Generic code, use for newly FDA approved PET diagnostic radiopharmaceutic als | NA | NA | NI | N | Packaged into APC rate | Packaged into APC rate | Packaged into APC rate |
| A9599 | Radioph dx b amyloid pet nos |  |  |  |  | N | Packaged into APC rate | Packaged into APC rate | Packaged into APC rate |
| A9606 | Radium Ra-223 dichloride, therapeutic, per microcurie dose | $\begin{gathered} \text { Xofigo }^{\text {TM }} \text { NDC } \\ \text { \#50419-0208-01 } \end{gathered}$ | 1745 | 1745 | K | K | \$128.53 | \$128.75 | 0.2\% |
| A9699 | Radiopharm rx agent noc RADIOPHARMACEUTICAL, THERAPEUTIC, NOT OTHERWISE CLASSIFIED | RX NOC |  |  | N | N | Packaged into APC rate | Packaged into APC rate | Packaged into APC rate |

**Note final payment rates for status G codes have offset RP amounts posted on the CMS web site by CPT code.

| J0153 | Adenosine inj 1mg | ADENOSCAN Replaces J0150, |  |  | N | N | Packaged into APC rate | Packaged into APC rate | Packaged into APC rate |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| J0280 | Aminophyllin up to 250 MG , inj. |  |  |  | N | N | Packaged into APC rate | Packaged into APC rate | Packaged into APC rate |
| J0461 | Inj , atropine sulfate, 0.01 mg |  |  |  | N | N | Packaged into APC rate | Packaged into APC rate | Packaged into APC rate |
| J1120 | Acetazolamide sodium injection, up to 500 mg | Diamox |  |  | N | N | Packaged into APC rate | Packaged into APC rate | Packaged into APC rate |
| J1160 | Inj, digoxin, up to 0.5 mg | Lanoxin |  |  | K | N | \$4.96 | Packaged into APC rate | Packaged into APC rate |
| J1245 | Dipyridamole injection, per 10 mg | Persantine IV |  |  | N | N | Packaged into APC rate | Packaged into APC rate | Packaged into APC rate |
| J1250 | Inj dobutamine HCL/250 mg | Dobutrex |  |  | N | N | Packaged into APC rate | Packaged into APC rate | $\begin{gathered} \text { Packaged } \\ \text { into APC rate } \\ \hline \end{gathered}$ |
| J1265 | Injection, dopamine $\mathrm{HCl}, 40 \mathrm{mg}$ | Intropin |  |  | N | N | $\begin{array}{\|c} \hline \text { Packaged into } \\ \text { APC rate } \\ \hline \end{array}$ | $\begin{gathered} \text { Packaged into } \\ \text { APC rate } \\ \hline \end{gathered}$ | $\begin{aligned} & \text { Packaged } \\ & \text { into APC rate } \end{aligned}$ |
| J1610 | Glucagon hydrochloride per 1MG | Glucagen | 9042 | 9024 | K | K | \$194.42 | \$200.82 | 3.3\% |
| J1800 | Propranolol HCL injection, up to 1 mg | Inderal |  |  | N | N | Packaged into APC rate | Packaged into APC rate | Packaged into APC rate |
| J1940 | Furosemide injection up to 20 mg | Lasix |  |  | N | N | Packaged into APC rate | Packaged into APC rate | Packaged into APC rate |
| J2270 | Morphine sulfate injection, up to 10 mg | Replaces J2271 |  |  | N | N | Packaged into APC rate | Packaged into APC rate | Packaged into APC rate |
| J2785 | Injection, Regadenoson, 0.1 milligrams | $\begin{aligned} & \text { LexiScan NDC } \\ & 00469-6501-89 \end{aligned}$ |  |  | N | N | Packaged into APC rate | Packaged into APC rate | Packaged into APC rate |


| CPT/ |  | Trade | $\begin{aligned} & \text { July- } \\ & 2017 \end{aligned}$ | $\begin{array}{\|c} 2018- \\ P \end{array}$ | July2017 | $\begin{gathered} 2018 \\ \mathbf{P} \end{gathered}$ | July 2017 Rates | Proposed Rule CY July 2018 | \% |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| HCPCS | Description | Name | APC | APC | SI | SI | Payment Rate | Payment Rate | Change |
| J2805 | Sincalide injection INJECTION, SINCALIDE, 5 MICROGRAMS | Kinevac® |  |  | N | N | Packaged into APC rate | Packaged into APC rate | Packaged into APC rate |
| J3240 | Thyrotropin injection 0.9 mg n 1.1 mg vial | Thyrogen Thytropar | 9108 | 9108 | K | K | \$1,569.54 | \$1,566.93 | -0.2\% |
| J3420 | Injection, vitamin B-12 cyanocobalamin, up to 1000 mcg |  |  |  | N | N | Packaged into APC rate | Packaged into APC rate | Packaged into APC rate |
| J7030 | Normal saline solution infus (1000 CC) |  |  |  | N | N | Packaged into APC rate | Packaged into APC rate | Packaged into APC rate |
| J7040 | Normal saline solution infus ( $500 \mathrm{ML}=1$ ) |  |  |  | N | N | Packaged into APC rate | Packaged into APC rate | Packaged into APC rate |
| J7050 | Normal saline solution infus (250 CC) |  |  |  | N | N | Packaged into APC rate | Packaged into APC rate | Packaged into APC rate |
| J9310 | Rituximab, 100 mg | RituXan | 0849 | 0849 | K | K | \$842.39 | \$818.31 | -2.9\% |
| G3001 | Admin + supply, tositumomab, 450 mg (Use this Code for Bexxar) | Non Radioactive Bexxar Plus Iniection | 5701 | Deleted | S | D | \$1,971.61 | Deleted | Deleted |
| Q9982 | Flutemetamol F-18, diagnostic, per study dose, up to 5 millicuries |  | 9459 | 9459 | G | G | NA | \$3,498.00 | NA |
| Q9983 | Florbetaben F-18, diagnostic, per study dose, up to 8.1 millicuries | Neuracec ${ }^{\text {'m }}$ <br> Piramal NDC \# <br> 54828-001-30 | 9458 | 9458 | G | G | NA | \$2,968.00 | NA |
| Q9968 | Injection, non-radioactive, non-contrast, visualization adjunct (e.g., Methylene Blue, Isosulfan Blue), 1 mg | Methylene Blue | 1446 | 1446 | K | N | \$4.29 | NA | NA |

## Disclaimer

The opinions referenced are those of the members of the SNMMI Coding and Reimbursement Committee and their consultants based on their coding experience. They are based on the commonly used codes in Nuclear Medicine, which are not all inclusive. Always check with your local insurance carriers as policies vary by region. The final decision for the coding of a procedure must be made by the physician considering regulations of insurance carriers and any local, state or federal laws that apply to the physicians practice. The SNMMI and its representatives disclaim any liability arising from the use of these opinions.
Legend: $\Delta$ Blue triangle - current code revision has resulted in a substantially altered procedure descriptor • Red circle - new procedure

